The medical condition or reason for a Sexual Health and HIV Episode.

The following codes are used within the data set:

 Diagnosis and/or treatment of infection or disease  
A1Primary syphilis
A2Secondary syphilis
A3Early latent syphilis
A4Cardiovascular syphilis
A6All other late and latent syphilis
A7ACongenital syphilis
A10Ocular syphilis
C2Lymphogranuloma venereum (LGV)
C4Chlamydial infection
C4NNon-specific genital infection (NSGI)
C5APelvic inflammatory disease (PID) and epididymitis
C5BOphthalmia neonatorum
C6BAnaerobic/Bacterial vaginosis and anaerobic balanitis
C6COther vaginosis/vaginitis/balanitis
C7AAnogenital candidosis
C9Pediculosis pubis
C10AAnogenital Herpes simplex: First episode
C10BAnogenital Herpes simplex: Recurrent episode
C11AAnogenital warts infection: First episode
C11DAnogenital warts infection: Recurrent episode
C12Molluscum contagiosum
C13Viral hepatitis B (HbsAg positive): First diagnosis
C14Viral hepatitis C: First diagnosis
C15Viral hepatitis A: Acute infection
C16Mycoplasma genitalium
D2AUrinary Tract Infection
D2BOther conditions requiring treatment at Level 3 Genitourinary Medicine Services
HHIV positive - Previously Diagnosed
H1New HIV diagnosis
H1ANew HIV diagnosis: Acute
H1BNew HIV diagnosis: Late infection (AIDS defined)
H2Attendance for HIV-related care
P4ACervical cytology: minor abnormality
P4BCervical cytology: major abnormality
 Sexual Health Services Provided
To record PATIENTS receiving Sexual Health Services or undergoing tests.
T1Chlamydia test
T2Chlamydia and gonorrhoea tests
T3Chlamydia, gonorrhoea and syphilis tests
T4Chlamydia, gonnorrhoea, syphilis and HIV antibody tests
T5Herpes Simplex Virus (HSV) Test
T6Hepatitis A/B/C Test
TT3 Site Testing (chlamydia and gonorrhoea)
T7Syphilis and HIV Testing
T8Self sampling (urinalysis/swabs) without Health Care worker (HCW) consultation
T9STI testing not required/appropriate
T10Rapid testing (STI and/or HIV)
T11Chlamydia test declined
T12Mycoplasma genitalium test
O20Hepatitis A vaccination: 1st dose
O21Hepatitis A vaccination: Subsequent dose
O22Hepatitis A immune
O23Partner notification related attendance: Hepatitis A contact
O31PrEP eligibility criteria 1: MSM/transgender woman
O32PrEP eligibility criteria 2: HIV positive partner
O33PrEP eligibility criteria 3: Other high risk
O41PrEP regimen: Starting or continuing daily Prep
O42PrEP regimen: Starting or continuing event based Prep
O43PrEP regimen: Continued through other source
O44PrEP regimen: Offered and declined
O45PrEP regimen: Stopped
O51PrEP prescription: 30 tablets
O52PrEP prescription: 60 tablets
O53PrEP prescription: 90 tablets
O60PrEP patient characteristic: Transgender
P1AHuman Immunodeficiency Virus (HIV) antibody test (no sexual health screen)
P1BHuman Immunodeficiency Virus (HIV) antibody test offered and refused
P1CHIV test inappropriate
P2AHepatitis B vaccination: 1st dose
P2BHepatitis B vaccination: 2nd dose
P2CHepatitis B vaccination: 3rd dose
P2DHepatitis B vaccination: 4th dose
P2EHepatitis B vaccination: Booster
P2IHepatitis B immune
P3CONTRACEPTION and family planning advice (excluding condom provision)
P4Cervical cytology done
REF1Referral from Chlamydia Screening Programme
REF2Referral to a Level 3 Genitourinary Medicine Service
REF3Referral from home testing/sampling service
SG1Shigella flexneri (group B)
SG2Shigella sonnei (group D)
SG3Shigella other/unspecified
SRHSexual and Reproductive Health PATIENT
W1HPV vaccination: 1st dose
W2HPV vaccination: 2nd dose
W3HPV vaccination: 3rd dose
W4HPV vaccination: offered and declined
W5HPV vaccination: previously received in full
PNPartner notification initiated related attendance
PNCPartner notification related attendance: Chlamydia contact
PNGPartner notification related attendance: Gonorrhoea contact
PNHPartner notification related attendance: HIV contact
PNNPartner notification related attendance: Non-specific genital infection contact
PNPPartner notification related attendance: PID/Epididymitis contact
PNSPartner notification related attendance: Syphilis contact
PNTPartner notification related attendance: Trichomoniasis contact
PR1Pregnant 1-12 weeks
PR2Pregnant 13-28 weeks
PR3Pregnant 29-40 weeks
PEPSPost exposure prophylaxis after sexual exposure (PEPSE)
D3Other Sexual Health and HIV Episodes not requiring treatment
O11-O99Research/New/Urgent reporting (Retired 01 October 2018)
40Sexual Assault (Acute presentation)
41Sexual Assault (Non - acute presentation)
CSE1Child sexual exploitation : concerns raised at internal assessment
CSE2Child sexual exploitation : concerns raised with internal safeguarding professionals
CSE3Child sexual exploitation : referred to external safeguarding professionals
DVConcern of domestic violence (or abuse)
FGMFemale genital mutilation (of any type)
 Special PATIENT Groups
To record additional information on certain PATIENT groups receiving Sexual Health Services or undergoing tests. Codes to be reported separately at each FIRST ATTENDANCE.
SWSex Worker
 Suffixes to Codes
To record additional information about the PATIENT’s presentation or a Sexual Health Service given. This information may be collected through the use of suffixes which can be applied to the SEXUAL HEALTH AND HIV ACTIVITY PROPERTY TYPE. Where appropriate, multiple suffixes can be used on the same SEXUAL HEALTH AND HIV ACTIVITY PROPERTY TYPE. The suffixes and the codes with which they can be used are given below. These codes are appended to the SEXUAL HEALTH AND HIV ACTIVITY PROPERTY TYPE.
RRectal infection
OPharyngeal infection
XPreviously diagnosed elsewhere
MMedication given
QQuadrivalent HPV vaccine
 Permissible Code Permutations Using Suffixes
 A - Syphilis
A1XPrimary syphilis - previously diagnosed elsewhere
A2XSecondary syphilis - previously diagnosed elsewhere
A3XEarly latent syphilis - previously diagnosed elsewhere
A4XCardiovascular syphilis - previously diagnosed elsewhere
A5XNeurosyphillis syphilis - previously diagnosed elsewhere
A6XAll other late and latent syphilis - previously diagnosed elsewhere
A7AXCongenital syphilis - previously diagnosed elsewhere
 B - Gonorrhoea
BRGonorrhoea - rectal infection
BOGonorrhoea - pharayngeal infection
BXGonorrhoea - previously diagnosed elsewhere
BMGonorrhoea - medication given
BRXGonorrhoea - rectal infection, previously diagnosed elsewhere
BRMGonorrhoea - rectal infection, medication given
BOXGonorrhoea - pharayngeal infection, previously diagnosed elsewhere
BOMGonorrhoea - pharayngeal infection, medication given
 C4 - Chlamydia
C4RChlamydia - rectal infection
C4OChlamydia - pharayngeal infection
C4XChlamydia - previously diagnosed elsewhere
C4MChlamydia - medication given
C4RXChlamydia - rectal infection, previously diagnosed elsewhere
C4RMChlamydia - rectal infection, medication given
C4OXChlamydia - pharayngeal infection, previously diagnosed elsewhere
C4OMChlamydia - pharayngeal infection, medication given
 C2 - Lymphogranuloma (LGV)
C2RLymphogranuloma venereum (LGV) - Rectal infection
C2OLymphogranuloma venereum (LGV) - Pharayngeal infection
C4NRNon-specific genital infection (NSGI) - rectal infection (proctitis)
 C6A - Trichomoniasis
C6AXTrichomoniasis - previously diagnosed elsewhere
 H1 - New HIV diagnosis
H1XNew HIV diagnosis - previously diagnosed elsewhere
 H1A - New HIV diagnosis: acute
H1AXNew HIV diagnosis: acute - previously diagnosed elsewhere
 H1B - HIV diagnosis: late (AIDS defined)
H1BXNew HIV diagnosis: late (AIDS defined) - previously diagnosed elsewhere
 C10A - Anogenital Herpes simplex: first episode
C10AMAnogenital Herpes simplex: first episode - medication given
 C10B - Anogenital Herpes simplex: recurrent episode
C10BMAnogenital Herpes simplex: recurrent episode - medication given
 C11A - Anogenital warts infection: first episode
C11AMAnogenital warts infection: first episode - medication given
 C11D - Anogenital warts infection: recurrent episode
C11DMAnogenital warts infection: recurrent episode - medication given
 W1 - HPV Vaccination: 1st dose
W1QHPV Vaccination: 1st dose - quadrivalent vaccine
 W2 - HPV Vaccination: 2nd dose
W2QHPV Vaccination: 2nd dose - quadrivalent vaccine
 W3 - HPV Vaccination: 3rd dose
W3QHPV Vaccination: 3rd dose - quadrivalent vaccine

This attribute is also known by these names: